Frederic Amar joined the Group’s Board as Non-Executive Director in November 2013 and was appointed Executive Director and CEO in March 2014. Mr. Amar has a strong scientific background and a successful track record creating and managing companies. In 1995 Mr. Amar founded ATelecom S.A., a national fully licenced private telecom operator concentrated on business customers and consumers, which after successful growth was sold in March 2000.In addition to other companies, in November 2011 Mr. Amar also founded Salveo Biotechnology S.A., a Geneva based private laboratory specialised in stem cells cryopreservation and cell culture and involved in cellular therapeutic applications research, with a presence in Italy, Spain, Switzerland, Portugal and Ukraine.
Mr. Amar holds a degree in Crystallography and a degree in Pharmacy (Pharm.D.) from the Université de Pharmacie of Marseilles.
Because of his share interest in the Group, Mr. Amar is not considered to be independent in the meaning of the Dutch Corporate Governance Code.
Mr. Amar’s current term expires on the date of the annual general meeting of 2018.
Gert-Jan van der Marel joined the Group´s Board as Non-Executive Director in November 2013 and was appointed Chairman of the Board inOctober 2014. Mr. Van der Marel has broad knowledge of and expertise in turnaround management and more than 30 years’ experience in international management. Major milestones of his professional career include positions as Senior Consultant with Arthur D. Little International, Managing Director of P.T. Friesche Vlag Indonesia/P.T. Foremost Indonesia, Managing Director Vlisco BV, Member of the Executive Board Koninklijke Grolsch N.V., Partner and Co-Founder of Xperience Partners B.V., CEO of Zurel Group B.V. and partner of Bakkenist Management Consultants.
Mr. Van der Marel holds a Master degree in Business Economics from the University of Groningen, The Netherlands and an MBA from INSEAD, Fontainebleau, France.
Mr. Van der Marel’s current term expires on the date of the annual general meeting of 2019.
Dr. Ronald Lorijn (MD, PhD, MBA), business consultant in biotechnology, joined the Group as a Non-Executive Director in May 2010. Dr. Lorijn also serves on the board of Pepscan Therapeutics and nLife. Previously, Dr. Lorijn was Chief Executive of AMT N.V. (Amsterdam), having developed AMT from a small, one-product operation into a leading gene therapy Group listed on NASDAQ in NY. He retired from AMT in February 2009. Prior to AMT, Dr. Lorijn worked at Amgen, a leading human therapeutics Group, where he was part of Amgen Europe´s executive management team and responsible for its Clinical Operations, Business Development & Governmental Affairs. Before joining Amgen he was Chief Medical Officer and Senior Director of Clinical Operations & Medical Affairs, Europe at Centocor after having been employed by the pharmaceutical division of AKZO (Organon), as its head of worldwide Medical Services and Product Surveillance.
Dr. Lorijn graduated from the Radboud University Nijmegen, completed a Ph.D. and was a certified obstetrician / gynaecologist before joining the biotech industry.
Mr. Lorijn’s current term expires on the date of the annual general meeting of 2017.
Mr. Vincent Borgeot is the founder, chairman and CEO of Fox Finance, a boutique advisory company based in Geneva that assists corporate clients and high net worth individuals in their cross border investment strategies for acquisitions, disposals or business development in private equity, listed companies or capital development. Prior to founding Fox Finance, he was Vice President Development and Control at Groupe Arnault – the ultimate parent company of LVMH and Dior Group – and Group Accor – Wagonlit Travel.
Mr. Borgeot earned his Master’s degree in Science (in Aeronautics) from ISAE-SUPAERO in Toulouse, France and an MBA from the HEC School of Management, where he also served as an assistant teacher in Strategic Planning.
Mr. Borgeot’s current term expires on the date of the annual general meeting of 2018.